STAT+: Pharmalittle: We’re reading about Merck halting U.K. research plans, pharma interest in psychedelics, and more
4.3
来源：
STAT
发布时间：
2025-09-11 10:00
摘要：
Merck has halted its research operations in the U.K., citing dissatisfaction with the government's pricing policies for innovative medicines. This decision reflects a broader trend where the pharmaceutical industry is increasingly frustrated with the U.K.'s failure to support R&D investments. A recent report indicates that the U.K. has fallen in attractiveness for foreign investment in pharmaceuticals, with significant declines in R&D funding attributed to high repayment rates on sales to the NHS.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
0.5
business_impact
1.0
scientific_rigor
0.0
timeliness_innovation
0.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.0
technical_barrier_competition
0.0
关键证据
Merck decided to halt research operations in the U.K.
The U.K.'s position for attracting foreign direct investment fell from second in 2017 to seventh in 2023.
High clawback rates on pharmaceutical companies’ revenues dampen investor confidence.
真实性检查
否
AI评分总结
Merck has halted its research operations in the U.K., citing dissatisfaction with the government's pricing policies for innovative medicines. This decision reflects a broader trend where the pharmaceutical industry is increasingly frustrated with the U.K.'s failure to support R&D investments. A recent report indicates that the U.K. has fallen in attractiveness for foreign investment in pharmaceuticals, with significant declines in R&D funding attributed to high repayment rates on sales to the NHS.